GI
AVIR icon

GAMMA Investing’s Atea Pharmaceuticals AVIR Stock Holding History

GAMMA Investing’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423 Sell
91
-18
-17% -$90 ﹤0.01% 4010
2026
Q1 		$586 Buy
+109
New +$501 ﹤0.01% 3923

Other funds holding AVIR

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
CAC
Certified Advisory Corp Altamonte Springs, Florida $1.24B AUM 21.71% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's AVIR Position: Q2 2026 in Review

GAMMA Investing reduced its Atea Pharmaceuticals (AVIR) stake by 17% in Q2 2026, selling an estimated $90 and leaving 91 shares worth $423. The position accounts for ﹤0.01% of the portfolio, ranked #4010.

GAMMA Investing first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $586 in Q1 2026. 8 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • GAMMA Investing held 91 shares of Atea Pharmaceuticals worth $423 as of Q2 2026.
  • GAMMA Investing sold 18 Atea Pharmaceuticals shares in Q2 2026, an estimated $90.
  • Atea Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4010 holding.
  • GAMMA Investing first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Atea Pharmaceuticals position peaked at $586 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.